scholarly article | Q13442814 |
P50 | author | Matthias J. Schnell | Q61864440 |
James P McGettigan | Q91280200 | ||
P2093 | author name string | Elizabeth J Faul | |
Phyllis Flomenberg | |||
Emily A Gomme | |||
P2860 | cites work | Concepts in the pathogenesis of rabies | Q39965361 |
Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. | Q40361792 | ||
The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection | Q40390611 | ||
The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope | Q40716670 | ||
Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: an in vitro and in vivo study | Q40860222 | ||
Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system. | Q41689082 | ||
Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. | Q42036085 | ||
Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity | Q43178486 | ||
SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector | Q45395971 | ||
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease | Q45406650 | ||
Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses | Q45413779 | ||
Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription | Q45802541 | ||
Measurement of polyclonal and antigen-specific cytotoxic T cell function | Q46630058 | ||
A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing Cells | Q57077896 | ||
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime–boost approach | Q57165945 | ||
Global epidemiology of HIV | Q57871015 | ||
Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus | Q27469800 | ||
Interleukin-10 determines viral clearance or persistence in vivo | Q27486832 | ||
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells | Q29616205 | ||
HIV-prevention science at a crossroads: advances in reducing sexual risk. | Q30378142 | ||
Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates | Q33839981 | ||
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector | Q33854615 | ||
Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies | Q33911986 | ||
A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector | Q34092753 | ||
Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. | Q34334320 | ||
Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic | Q34461764 | ||
Replication-defective viruses as vaccines and vaccine vectors | Q34477918 | ||
Budding of rabies virus particles in the absence of the spike glycoprotein | Q34662773 | ||
HIV-1 vaccines: the search continues | Q34876150 | ||
A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection | Q35853085 | ||
DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge | Q36129034 | ||
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice | Q36423935 | ||
Genetic recombination during coinfection of two mutants of human respiratory syncytial virus | Q36474033 | ||
The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread | Q36483804 | ||
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial | Q36618096 | ||
Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene | Q37068893 | ||
Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. | Q37174356 | ||
Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles | Q37249987 | ||
Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein | Q37250302 | ||
Retrograde neuronal tracing with a deletion-mutant rabies virus | Q37370635 | ||
Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus | Q37600266 | ||
Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque | Q37683291 | ||
Differential transcription attenuation of rabies virus genes by intergenic regions: generation of recombinant viruses overexpressing the polymerase gene | Q39592571 | ||
P433 | issue | 6 | |
P921 | main subject | vector-borne disease | Q2083837 |
rabies | Q39222 | ||
rabies virus | Q698976 | ||
P304 | page(s) | 2820-2831 | |
P577 | publication date | 2010-01-06 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | Characterization of a single-cycle rabies virus-based vaccine vector | |
P478 | volume | 84 |
Q38960717 | A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region |
Q36356863 | A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence |
Q35803316 | A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus |
Q34414740 | An anterograde rabies virus vector for high-resolution large-scale reconstruction of 3D neuron morphology |
Q27334697 | Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine |
Q42276697 | Axonal and subcellular labelling using modified rabies viral vectors |
Q41923775 | Combining confocal and atomic force microscopy to quantify single-virus binding to mammalian cell surfaces. |
Q34806497 | Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses |
Q35184639 | Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine |
Q41217724 | Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity |
Q39529861 | Development of recombinant rabies viruses vectors with Gaussia luciferase reporter based on Chinese vaccine strain CTN181. |
Q37798009 | Experimental rabies vaccines for humans |
Q37951526 | From brain passage to cell adaptation: the road of human rabies vaccine development |
Q36210186 | Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein |
Q36312553 | Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression |
Q35275167 | Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses |
Q34261441 | Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus |
Q28397551 | Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways |
Q38266413 | RNA-based viral vectors |
Q39633419 | Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. |
Q37877958 | Rabies virus as a research tool and viral vaccine vector |
Q42051356 | Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice. |
Q37543755 | Reverse Genetics Approaches to Control Arenavirus. |
Q38363535 | Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics |
Q34992537 | Rhabdovirus-based vaccine platforms against henipaviruses |
Q35150964 | Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses |
Q90024491 | Vaccination with a Single-Cycle Respiratory Syncytial Virus Is Immunogenic and Protective in Mice |
Q38885624 | Viral and Synthetic RNA Vector Technologies and Applications |
Q47239972 | Virus stamping for targeted single-cell infection in vitro and in vivo |
Search more.